134 related articles for article (PubMed ID: 23607597)
21. Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone.
Vyas AR; Singh SV
AAPS J; 2014 Jan; 16(1):1-10. PubMed ID: 24046237
[TBL] [Abstract][Full Text] [Related]
22. PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells.
Rah B; ur Rasool R; Nayak D; Yousuf SK; Mukherjee D; Kumar LD; Goswami A
Autophagy; 2015; 11(2):314-31. PubMed ID: 25803782
[TBL] [Abstract][Full Text] [Related]
23. Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells.
Kakar SS; Ratajczak MZ; Powell KS; Moghadamfalahi M; Miller DM; Batra SK; Singh SK
PLoS One; 2014; 9(9):e107596. PubMed ID: 25264898
[TBL] [Abstract][Full Text] [Related]
24. Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer.
Nagalingam A; Kuppusamy P; Singh SV; Sharma D; Saxena NK
Cancer Res; 2014 May; 74(9):2617-29. PubMed ID: 24732433
[TBL] [Abstract][Full Text] [Related]
25. Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells.
Kim SH; Singh SV
Cancer Prev Res (Phila); 2014 Jul; 7(7):738-47. PubMed ID: 24824039
[TBL] [Abstract][Full Text] [Related]
26. Withaferin A inhibits matrix metalloproteinase-9 activity by suppressing the Akt signaling pathway.
Lee DH; Lim IH; Sung EG; Kim JY; Song IH; Park YK; Lee TJ
Oncol Rep; 2013 Aug; 30(2):933-8. PubMed ID: 23708780
[TBL] [Abstract][Full Text] [Related]
27. Correction to "The tumor proteasome is a primary target for the natural anticancer compound withaferin A isolated from 'Indian winter cherry'".
Mol Pharmacol; 2015 May; 87(5):865. PubMed ID: 25814535
[No Abstract] [Full Text] [Related]
28. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells.
Li X; Zhu F; Jiang J; Sun C; Wang X; Shen M; Tian R; Shi C; Xu M; Peng F; Guo X; Wang M; Qin R
Cancer Lett; 2015 Feb; 357(1):219-230. PubMed ID: 25444914
[TBL] [Abstract][Full Text] [Related]
29. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
30. Molecular docking, QSAR and ADMET studies of withanolide analogs against breast cancer.
Yadav DK; Kumar S; Saloni ; Singh H; Kim MH; Sharma P; Misra S; Khan F
Drug Des Devel Ther; 2017; 11():1859-1870. PubMed ID: 28694686
[TBL] [Abstract][Full Text] [Related]
31. Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A.
Samanta SK; Sehrawat A; Kim SH; Hahm ER; Shuai Y; Roy R; Pore SK; Singh KB; Christner SM; Beumer JH; Davidson NE; Singh SV
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28040797
[TBL] [Abstract][Full Text] [Related]
32. Evaluation and Comparison of the In Vitro Cytotoxic Activity of Withania somnifera Methanolic and Ethanolic Extracts against MDA-MB-231 and Vero Cell Lines.
Srivastava AN; Ahmad R; Khan MA
Sci Pharm; 2016; 84(1):41-59. PubMed ID: 27110497
[TBL] [Abstract][Full Text] [Related]
33. Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown.
Kim SH; Hahm ER; Arlotti JA; Samanta SK; Moura MB; Thorne SH; Shuai Y; Anderson CJ; White AG; Lokshin A; Lee J; Singh SV
Breast Cancer Res Treat; 2016 May; 157(1):41-54. PubMed ID: 27097807
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells.
Szarc vel Szic K; Op de Beeck K; Ratman D; Wouters A; Beck IM; Declerck K; Heyninck K; Fransen E; Bracke M; De Bosscher K; Lardon F; Van Camp G; Vanden Berghe W
PLoS One; 2014; 9(2):e87850. PubMed ID: 24498382
[TBL] [Abstract][Full Text] [Related]
35. Growth arrest by the antitumor steroidal lactone withaferin A in human breast cancer cells is associated with down-regulation and covalent binding at cysteine 303 of β-tubulin.
Antony ML; Lee J; Hahm ER; Kim SH; Marcus AI; Kumari V; Ji X; Yang Z; Vowell CL; Wipf P; Uechi GT; Yates NA; Romero G; Sarkar SN; Singh SV
J Biol Chem; 2014 Jan; 289(3):1852-65. PubMed ID: 24297176
[TBL] [Abstract][Full Text] [Related]
36. Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors.
Lee J; Hahm ER; Marcus AI; Singh SV
Mol Carcinog; 2015 Jun; 54(6):417-29. PubMed ID: 24293234
[TBL] [Abstract][Full Text] [Related]
37. Anti-proliferative withanolides from the Solanaceae: a structure-activity study.
Zhang H; Samadi AK; Cohen MS; Timmermann BN
Pure Appl Chem; 2012; 84(6):1353-1367. PubMed ID: 24098060
[TBL] [Abstract][Full Text] [Related]
38. Role of mitogen-activated protein kinases and Mcl-1 in apoptosis induction by withaferin A in human breast cancer cells.
Hahm ER; Lee J; Singh SV
Mol Carcinog; 2014 Nov; 53(11):907-16. PubMed ID: 24019090
[TBL] [Abstract][Full Text] [Related]
39.
Lerose V; Ponticelli M; Benedetto N; Carlucci V; Lela L; Tzvetkov NT; Milella L
Plants (Basel); 2024 Mar; 13(6):. PubMed ID: 38592845
[No Abstract] [Full Text] [Related]
40. Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms.
Xing Z; Su A; Mi L; Zhang Y; He T; Qiu Y; Wei T; Li Z; Zhu J; Wu W
Drug Des Devel Ther; 2023; 17():2909-2929. PubMed ID: 37753228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
